Nerve News and Research

RSS

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK.

25 Jun 2010

Ways to manage hammertoe pain

The pain from hammertoe, a deformity that can cause one or more toes to assume a claw shape, can curtail an evening of dancing or make a favorite pair of shoes unwearable. But, according to the June issue of Mayo Clinic Health Letter, this condition often can be managed by proper footwear or simple toe coverings.

24 Jun 2010

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.

24 Jun 2010

Treatment options for patients with MS

The best one-word description for multiple sclerosis is "unpredictable," according to the June issue of Mayo Clinic Women's HealthSource. MS interferes with the communication between the brain and the rest of the body. Just how that interference plays out in symptoms is different for everyone -- thus, the unpredictable label.

24 Jun 2010

Researchers study why the brain of newborn baby is particularly flexible

Science has long puzzled over why a baby's brain is particularly flexible and why it easily changes. Is it because babies have to learn a lot? A group of researchers from the Bernstein Network Computational Neuroscience, the Max Planck Institute for Dynamics and Self-Organization in G-ttingen, the Schiller University in Jena and Princeton University have now put forward a new explanation: Maybe it is because the brain still has to grow.

23 Jun 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

For the very first time, a medicine has been shown to protect against the development of Alzheimer's disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761 per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer's disease by nearly 50%.

23 Jun 2010

REM sleep deprivation leads to changes in levels of key proteins that increase risk of migraine: Study

Reporting at the American Headache Society's 52nd Annual Scientific Meeting in Los Angeles this week, new research shows that sleep deprivation leads to changes in the levels of key proteins that facilitate events involved in the underlying pathology of migraine.

23 Jun 2010

Baxano closes $30M Series C round of venture funding

Baxano, Inc. today announced the closing of a $30 million Series C round of venture funding, led by new investor CMEA Capital. Funds were also contributed by new investors Kaiser Permanente Ventures and Affinity Capital Management and existing investors Prospect Venture Partners, Three Arch Partners, and Kearny Venture Partners.

22 Jun 2010

Discoveries in study and manipulation of human ES cells win first prize in research competition

World-recognized discoveries in the study and manipulation of human embryonic stem cells have won first prize in a prestigious applied research competition for a Hebrew University of Jerusalem researcher.

22 Jun 2010

Special public meeting to spotlight stem cell-based therapies for ALS

Local scientists, health advocates and leaders from the California Institute for Regenerative Medicine will gather in San Diego June 23 for a special public meeting to spotlight a new University of California, San Diego grant to pursue novel, fast-tracked stem cell-based therapies for amyotrophic lateral sclerosis, or Lou Gehrig's disease.

18 Jun 2010

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

18 Jun 2010

Researchers make significant headway in fight against SMA

Researchers at the University of Utah are making strides in understanding and combating a motor neuron disease known as Spinal Muscular Atrophy. The spinal muscular atrophies are a group of inherited diseases that cause progressive degeneration of motor nerves resulting in muscle weakness. The most common form of the disorder, due to the deletion of a critical gene on chromosome 5, is currently the leading cause of inherited infant and child mortality.

18 Jun 2010

Laboratory mouse study shows cold sensing neural circuits develop well after birth

Cold sensing neural circuits in newborn mice take around two weeks to become fully active, according to a new study. The finding adds to understanding of the cold sensing protein TRPM8 (pronounced trip-em-ate), first identified in a Nature paper in 2002 by David McKemy of the University of Southern California.

18 Jun 2010

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

Research studies may lead to future development of cell transplant therapy for ALS

The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.

17 Jun 2010

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

For patients with quadriplegia, mutism and lower cranial nerve paralysis (locked-in syndrome), their only means of interacting with others is through vertical gaze and upper eyelid movements, using eye-coded communication strategies.

17 Jun 2010

Dietary guideline on sodium puts Americans at risk

The Dietary Guidelines Advisory Committee (DGAC) of the U.S. Department of Health and Human Services and the U.S. Department of Agriculture may increase health risks, including obesity, by ignoring sound science as they announce recommendations to reduce sodium consumption to 1,500 mg per day, says the Salt Institute.

16 Jun 2010

Many Huntington's disease patients suffer from weight loss, sleeping problems

An aggregating protein causes many of the symptoms of Huntington's disease, an incurable and frequently fatal brain disorder. Mosaic winner Ahmad Aziz discovered that the abnormal protein also aggregates in the hypothalamus, the part of the brain that regulates the autonomic nervous system and the endocrine system.

16 Jun 2010

Study validates Grm1 protein as target for melanoma treatment

Research by investigators at The Cancer Institute of New Jersey (CINJ) is showing new promise in the treatment of melanoma, the most serious of skin cancers. The findings, published in the May 27, 2010, online edition of the Journal of Investigative Dermatology further validate the team's clinical and pre-clinical findings that blocking the signaling normally activated by a receptor called Grm1 results in decreased cell growth and decreased migration of melanoma cells, confirming that Grm1 is a potential target for the treatment of melanoma.

16 Jun 2010

Nerve News and Research

Quark Pharmaceuticals' siRNA drug candidates featured in two presentations at Glaucoma & Retinopathies 2010

Ways to manage hammertoe pain

Mutation in ion channel that changes its dynamics is implicated in epilepsy: Scientists

Treatment options for patients with MS

Researchers study why the brain of newborn baby is particularly flexible

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

REM sleep deprivation leads to changes in levels of key proteins that increase risk of migraine: Study

Baxano closes $30M Series C round of venture funding

Discoveries in study and manipulation of human ES cells win first prize in research competition

Special public meeting to spotlight stem cell-based therapies for ALS

University of Utah makes progress against SMA with support of Families of Spinal Muscular Atrophy

Researchers make significant headway in fight against SMA

Laboratory mouse study shows cold sensing neural circuits develop well after birth

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Research studies may lead to future development of cell transplant therapy for ALS

Gabapentin shows effective in patients with locked-in syndrome, opsoclonus-myoclonus syndrome

Dietary guideline on sodium puts Americans at risk

Many Huntington's disease patients suffer from weight loss, sleeping problems

Study validates Grm1 protein as target for melanoma treatment

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News